Skip to content

Riva Leaving Gilead Sciences for CEO Post at Glenmark

March 5, 2019

Gilead Sciences Inc. (GILD) said Tuesday that Alessandro Riva, M.D, the company’s executive vice president of Oncology Therapeutics, will leave at the end of the month, and Glenmark Pharmaceuticals said he is joining their newly spun off innovation company as the new chief executive officer.

Glenmark said Dr. Riva’s appointment will be effective April 2.

“We are pleased that Alessandro will assume the role of CEO of the new innovation business,” said Glenn Saldanha, chairman and managing director of Glenmark Pharmaceuticals. “His extensive and diverse industry experience leading global R&D will no doubt be invaluable in driving our pipeline toward commercialization. We are excited for this major step as a company and are confident Alessandro’s talent and leadership will shape the innovation business into a major global biotech company.”

Dr. Riva joined Gilead in January 2017 with the title senior vice president, Hematology and Oncology Therapeutics Area Head. He was instrumental in expanding the company’s oncology programs, playing a critical role in the acquisition of Kite Pharma and guiding the strategy and development of Gilead’s broader oncology pipeline, the company said.

“Under Alessandro’s oversight, Gilead has expanded its work in the field of oncology and established itself as the leader in cell therapy with the acquisition of Kite,” said John McHutchison, AO, MD, the company’s chief scientific officer and head of research and development.

Gilead Sciences has commenced a search for Dr. Riva’s replacement.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: